Ventavis ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	28

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

diseases per page:

Showing 1 to 10 of 28 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03293407 (ClinicalTrials.gov)	February 1, 2018	20/9/2017	Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physica ...	Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinic ...	Hypertension, Pulmonary	Drug: Iloprost (Ventavis, BAYQ6256);Device: Breelib nebulizer	Bayer	NULL	Completed	18 Years	N/A	All	31		Germany
2	NCT02826252 (ClinicalTrials.gov)	September 15, 2016	5/7/2016	Examination of Ventavis(Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pu ...	VENTASWITCH, Examination of Ventavis® (Iloprost) Inhalation Behavior Using the I-Neb® AAD® System in ...	Hypertension, Pulmonary	Drug: Iloprost,(Ventavis, BAYQ6256);Device: I-Neb AAD system	Bayer	NULL	Completed	18 Years	N/A	All	64	N/A	Germany
3	NCT02825160 (ClinicalTrials.gov)	August 1, 2016	15/6/2016	Non-interventional, Postauthorization Safety Study of Ventavisfor Pulmonary Arterial Hypertension (P ...	Drug Use Investigation of Ventavis for Pulmonary Arterial Hypertension (PAH)	Hypertension, Pulmonary	Drug: Ventavis (Iloprost, BAYQ6256)	Bayer	NULL	Recruiting	N/A	N/A	All	270		Japan
4	EUCTR2014-000091-25-GB (EUCTR)	01/09/2014	11/07/2014	A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Venta ...	A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Venta ...	Pulmonary Arterial Hypertension Eisenmenger syndrome MedDRA version: 17.0;Level: LLT;Classification ...	Trade Name: Iloprost Product Name: Ventavis INN or Proposed INN: Iloprost	Royal Brompton and Harefield NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	15	Phase 4	United Kingdom
5	NCT02032836 (ClinicalTrials.gov)	March 10, 2014	9/1/2014	Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)	A Multi-center, Open-label, Randomized Cross-over Study to Compare the Acute Tolerability and Pharma ...	Pulmonary Arterial Hypertension	Drug: lloprost(Ventavis,BAYQ6252, 20 µg/mL);Drug: lloprost(Ventavis,BAYQ6252, 10 µg/mL)	Bayer	NULL	Completed	18 Years	N/A	All	27	Phase 1/Phase 2	Austria;Germany
6	EUCTR2013-002783-12-DE (EUCTR)	07/01/2014	18/09/2013	No	A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharma ...	Patients with Pulmonary arterial hypertension, WHO class III, who have been on therpay with Ventavis ...	Trade Name: Ventavis10 Product Name: Ventavis10 Product Code: Bay Q 6256 INN or Proposed INN: ILOPROST T ...	Bayer HealthCare AG	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 1;Phase 2	Austria;Germany
7	EUCTR2013-002783-12-AT (EUCTR)	02/12/2013	18/10/2013	No	A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharma ...	Patients with Pulmonary arterial hypertension, WHO class III, who have been on therpay with Ventavis ...	Trade Name: Ventavis10 Product Name: Ventavis10 Product Code: Bay Q 6256 INN or Proposed INN: ILOPROST T ...	Bayer AG	NULL	Not Recruiting			Female: yes Male: yes	24	Phase 1;Phase 2	Austria;Germany
8	NCT01894035 (ClinicalTrials.gov)	September 23, 2013	3/7/2013	Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hype ...	Study to Assess the Compliance of Patients With Pulmonary Arterial Hypertension Treated With Inhaled ...	Pulmonary Hypertension	Drug: Iloprost (Ventavis, BAYQ 6256)	Bayer	NULL	Completed	18 Years	N/A	All	13		Portugal
9	NCT01781052 (ClinicalTrials.gov)	September 11, 2013	22/1/2013	Observational Description of Compliance for the Daily VentavisUse Via the Insight Program in Class I ...	DAILY: Observational Description of Compliance for the Daily Ventavis® Use Via the Insight Program i ...	Pulmonary Arterial Hypertension	Drug: Ventavis (Iloprost, BAYQ6256)	Bayer	NULL	Completed	18 Years	N/A	All	17	N/A	France
10	NCT01469169 (ClinicalTrials.gov)	June 19, 2012	8/11/2011	Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study	A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and P ...	Hypertension, Pulmonary	Drug: Iloprost (Ventavis inhaled, BAYQ6256)	Bayer	NULL	Completed	18 Years	75 Years	All	27	Phase 3	Japan

First Previous1 2 3Next Last